Treace Medical Elects Directors at Annual Meeting

The latest update is out from Treace Medical Concepts ( (TMCI) ).

At the 2025 Annual Meeting of Stockholders held on May 20, 2025, Treace Medical Concepts, Inc. announced the election of Lawrence W. Hamilton and Deepti Jain as Class I directors for a three-year term. Additionally, the stockholders approved the executive compensation on an advisory basis and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (TMCI) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Treace Medical Concepts stock, see the TMCI Stock Forecast page.

Spark’s Take on TMCI Stock

According to Spark, TipRanks’ AI Analyst, TMCI is a Neutral.

Treace Medical Concepts has shown revenue growth but is hindered by consistent financial losses and cash flow challenges. Technical indicators suggest bearish momentum, and the valuation is unattractive due to ongoing unprofitability. Earnings call data shows potential in product development but emphasizes the need for financial stability improvements.

To see Spark’s full report on TMCI stock, click here.

More about Treace Medical Concepts

Treace Medical Concepts, Inc. operates in the medical industry, focusing on providing innovative surgical solutions and products, particularly in the field of foot and ankle surgery.

Average Trading Volume: 463,191

Technical Sentiment Signal: Strong Sell

Current Market Cap: $423.4M

For an in-depth examination of TMCI stock, go to TipRanks’ Stock Analysis page.